Literature DB >> 22155821

Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Arnold Louie1, Brian D VanScoy, David L Brown, Robert W Kulawy, Henry S Heine, George L Drusano.   

Abstract

Bacillus anthracis, the bacterium that causes anthrax, is an agent of bioterrorism. The most effective antimicrobial therapy for B. anthracis infections is unknown. An in vitro pharmacodynamic model of B. anthracis was used to compare the efficacies of simulated clinically prescribed regimens of moxifloxacin, linezolid, and meropenem with the "gold standards," doxycycline and ciprofloxacin. Treatment outcomes for isogenic spore-forming and non-spore-forming strains of B. anthracis were compared. Against spore-forming B. anthracis, ciprofloxacin, moxifloxacin, linezolid, and meropenem reduced the B. anthracis population by 4 log(10) CFU/ml over 10 days. Doxycycline reduced the population of this B. anthracis strain by 5 log(10) CFU/ml (analysis of variance [ANOVA] P = 0.01 versus other drugs). Against an isogenic non-spore-forming strain, meropenem killed the vegetative B. anthracis the fastest, followed by moxifloxacin and ciprofloxacin and then doxycycline. Linezolid offered the lowest bacterial kill rate. Heat shock studies using the spore-producing B. anthracis strain showed that with moxifloxacin, ciprofloxacin, and meropenem therapies the total population was mostly spores, while the population was primarily vegetative bacteria with linezolid and doxycycline therapies. Spores have a profound impact on the rate and extent of killing of B. anthracis. Against spore-forming B. anthracis, the five antibiotics killed the total (spore and vegetative) bacterial population at similar rates (within 1 log(10) CFU/ml of each other). However, bactericidal antibiotics killed vegetative B. anthracis faster than bacteriostatic drugs. Since only vegetative-phase B. anthracis produces the toxins that may kill the infected host, the rate and mechanism of killing of an antibiotic may determine its overall in vivo efficacy. Further studies are needed to examine this important observation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155821      PMCID: PMC3294912          DOI: 10.1128/AAC.01109-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Authors:  Arnold Louie; Brian D Vanscoy; Henry S Heine; Weiguo Liu; Terry Abshire; Kari Holman; Robert Kulawy; David L Brown; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 3.  Antistaphylococcal agents.

Authors:  Howard S Gold; Satish K Pillai
Journal:  Infect Dis Clin North Am       Date:  2009-03       Impact factor: 5.982

4.  Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.

Authors:  G L Drusano; O O Okusanya; A O Okusanya; B van Scoy; D L Brown; C Fregeau; R Kulawy; M Kinzig; F Sörgel; H S Heine; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

5.  Antibiotics cure anthrax in animal models.

Authors:  Shay Weiss; David Kobiler; Haim Levy; Avi Pass; Yakir Ophir; Nili Rothschild; Arnon Tal; Josef Schlomovitz; Zeev Altboum
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

6.  Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.

Authors:  J Zimbelman; A Palmer; J Todd
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

7.  Effects of endogenous D-alanine synthesis and autoinhibition of Bacillus anthracis germination on in vitro and in vivo infections.

Authors:  Matthew T McKevitt; Katie M Bryant; Salika M Shakir; Jason L Larabee; Steven R Blanke; Julie Lovchik; C Rick Lyons; Jimmy D Ballard
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

8.  Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.

Authors:  Kerry L LaPlante; Steven N Leonard; David R Andes; William A Craig; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

9.  Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.

Authors:  Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

Authors:  G L Drusano; Olanrewaju O Okusanya; Adedoyin Okusanya; Brian Van Scoy; D L Brown; Robert Kulawy; Fritz Sörgel; Henry S Heine; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

View more
  8 in total

1.  Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.

Authors:  Carlos A Rodriguez; Maria Agudelo; Andres F Zuluaga; Omar Vesga
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.

Authors:  Trudy H Grossman; Michael S Anderson; Lindsay Drabek; Melanie Gooldy; Henry S Heine; Lisa N Henning; Winston Lin; Joseph V Newman; Rene Nevarez; Kaylyn Siefkas-Patterson; Anne K Radcliff; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.

Authors:  Arnold Louie; Brian Vanscoy; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

5.  Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrity.

Authors:  Yu-hua Xing; Wei Wang; Su-qin Dai; Ti-yan Liu; Jun-jie Tan; Guo-long Qu; Yu-xia Li; Yan Ling; Gang Liu; Xue-qi Fu; Hui-peng Chen
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

6.  Tetrazole-Based trans-Translation Inhibitors Kill Bacillus anthracis Spores To Protect Host Cells.

Authors:  John N Alumasa; Tyler D P Goralski; Kenneth C Keiler
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 7.  Alternative pre-approved and novel therapies for the treatment of anthrax.

Authors:  Breanne M Head; Ethan Rubinstein; Adrienne F A Meyers
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

8.  Impacts of indoor surface finishes on bacterial viability.

Authors:  Jinglin Hu; Sarah Ben Maamar; Adam J Glawe; Neil Gottel; Jack A Gilbert; Erica M Hartmann
Journal:  Indoor Air       Date:  2019-05-13       Impact factor: 5.770

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.